OR WAIT null SECS
The new interoperability rules could not have come at a better time.
Saying March has been a busy month for healthcare is an understatement. For the first time in 58 years, the HIMSS Global Health Conference & Exhibition - set to be held March 9-13 - was cancelled. Then, the Office of the National Coordinator for Health Information Technology and the Centers for Medicare & Medicaid Services issued final rules on interoperability and information blocking with the 21st Century Cures Act Final Rule. And on March 11, the World Health Organization (WHO) officially declared COVID-19 a pandemic.
The new interoperability rules could not have come at a better time as patients, providers and public health officials navigate what this pandemic means for them. Patients want to know if they are at-risk. They want to know when they should go see a doctor or what steps they should take. Providers want a way to triage patients to appropriate care (much of that being self-managed home care) and figure out how an influx of COVID-19 patients will fit into rapidly evolving workflows. Public health researchers, epidemiologists, and government officials need all-encompassing data, in a standardized format, to better understand this still-evolving disease and inform on guidelines.
The Final Rules in part addresses information-blocking practices and anti-competitive behaviors by healthcare providers, developers of certified health IT products, health information exchanges and other information networks. Finalizing the Cures Act coinciding with the COVID-19 pandemic creates an opportunity for collaboration and seamless information sharing across the industry.
Key Takeaways from the Final Interoperability Rules
Lack of interoperability has stood in the way of patients being able to manage their own health data. The Cures Act Final Rule is designed to change that, by:
Putting patients in the driver’s seat in terms of managing their own healthcare will be incredibly important in the context of COVID-19. It allows individuals to access their own data to help address their symptoms or access appropriate care, and it affords the opportunity for individuals to contribute their data for public health efforts to rapidly improve our understanding of COVID-19 in order to build better algorithms or identify effective treatments.
Specifically, there are three key ways the new interoperability rules can have a positive impact on how we address COVID-19.
Interoperability’s Role in the COVID-19 Pandemic
By standardizing the data through FHIR, we can greatly reduce the time and resources required to analyze that data and ultimately standardize our understanding of this emerging virus and the most effective interventions. This has been talked about in public health sectors for some time and this is our opportunity to put it into practice.
Our healthcare systems are being challenged and stretched in ways most providers have never experienced in their lifetime, requiring that we rapidly develop new workflows and healthcare delivery practices. In many systems, standard care is rapidly moving to virtual appointments or remote patient monitoring. To make this efficient, we need data exchange between EMRs, screening applications, remote monitoring platforms and telemedicine offerings. These new workflows will be the new normal for a while.
As COVID-19 continues to impact U.S. health systems, interoperability will continue to play an important role. There may very well be an uptick in adoption of remote patient monitoring and telehealth tools as health systems adapt to new workflows and challenges. Tools that are connected to the existing patient record and EHR will be essential in identifying patients most at risk, and assuring resources can be allocated rationally.
About the Author
Lucienne Marie Ide, M.D., PH.D., is the founder and chair ofRimidi, a cloud-based software platform that enables personalized management of health conditions across populations. She brings her diverse experiences in medicine, science, venture capital and technology to bear in leading Rimidi’s strategy and vision. Motivated by the belief that we can do so much better as individuals, an industry and society, Lucie left clinical medicine to join the ranks of healthcare entrepreneurs who are trying to revolutionize an industry.